Table 1.
Drug | FDA indications | EMA indications |
---|---|---|
Ipilimumab | Melanoma Non-small cell lung cancer Renal cell carcinoma |
Melanoma Non-small cell lung cancer Renal cell carcinoma data |
Nivolumab | Melanoma Non-small cell lung cancer Small cell lung cancer Renal cell cancer Classical Hodgkin’s lymphoma Squamous cell of esophagus or head and neck Urothelial cancer Colorectal cancer with microsatellite instability or mismatch-repair deficiency Hepatocellular carcinoma |
Melanoma Non-small cell lung cancer Renal cell cancer Classical Hodgkin’s lymphoma Squamous cell of esophagus or head and neck Urothelial cancer |
Pembrolizumab | Melanoma Non-small cell lung cancer Squamous cell of the head and neck Classical Hodgkin’s lymphoma Urothelial cancer Gastric cancer Esophageal cancer Cervical cancer Renal cell carcinoma Hepatocellular carcinoma Colorectal cancer with microsatellite instability or mismatch-repair deficiency |
Melanoma Non-small cell lung cancer Squamous cell of the head and neck Classical Hodgkin’s lymphoma Urothelial cancer Colorectal cancer with microsatellite instability or mismatch-repair deficiency |
Cemiplimab | Cutaneous cell carcinoma | Cutaneous cell carcinoma |
Atezolizumab | Urothelial carcinoma Non-small cell lung cancer Small-cell lung cancer Breast cancer Hepatocellular carcinoma |
Urothelial carcinoma Non-small cell lung cancer Small-cell lung cancer Breast cancer Hepatocellular carcinoma |
Avelumab | Merkel cell carcinoma Urothelial carcinoma Renal Cell carcinoma |
Merkel cell carcinoma Urothelial carcinoma Renal cell carcinoma |
Durvalumab | Urothelial carcinoma Non-small cell lung cancer |
Non-small cell lung cancer |